These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 10389911)

  • 1. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML; Grabstein KH; Sleath PR; Cheever MA
    Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL; Schiffman K; Cheever MA; Disis ML
    Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
    Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
    J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.
    Disis ML; Gralow JR; Bernhard H; Hand SL; Rubin WD; Cheever MA
    J Immunol; 1996 May; 156(9):3151-8. PubMed ID: 8617935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
    Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
    Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
    Salazar LG; Fikes J; Southwood S; Ishioka G; Knutson KL; Gooley TA; Schiffman K; Disis ML
    Clin Cancer Res; 2003 Nov; 9(15):5559-65. PubMed ID: 14654536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
    Disis ML; Gooley TA; Rinn K; Davis D; Piepkorn M; Cheever MA; Knutson KL; Schiffman K
    J Clin Oncol; 2002 Jun; 20(11):2624-32. PubMed ID: 12039923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
    Zaks TZ; Rosenberg SA
    Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
    Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
    Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of HER-2/neu-specific vaccines.
    Murray JL; Przepiorka D; Ioannides CG
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):71-5; discussion 92-100. PubMed ID: 11236031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
    Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
    Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
    J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.
    Salazar LG; Coveler AL; Swensen RE; Gooley TA; Goodell V; Schiffman K; Disis ML
    Clin Immunol; 2007 Dec; 125(3):275-80. PubMed ID: 17913588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
    Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Kao TC; Shriver CD; Ponniah S; Peoples GE
    Clin Cancer Res; 2006 Jan; 12(2):478-86. PubMed ID: 16428490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.
    Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y
    Clin Cancer Res; 2002 Nov; 8(11):3394-400. PubMed ID: 12429626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.